NR4A3 Antibody

What are the most validated applications for NR4A3 antibodies in research?

NR4A3 antibodies have been validated for multiple applications, with the most robust data supporting:

• Western Blotting (WB): Detects denatured NR4A3 protein, typically showing bands at approximately 65-68 kDa

• Immunohistochemistry (IHC): Both paraffin-embedded (IHC-p) and frozen sections (IHC-f)

• Immunofluorescence (IF): Demonstrates nuclear localization pattern

• Immunocytochemistry (ICC): For cellular localization studies

• ELISA: For quantitative detection

• Chromatin Immunoprecipitation (ChIP): For studying DNA-protein interactions

Most antibodies show strong nuclear staining patterns consistent with NR4A3's function as a transcription factor. For optimal results in diagnostic applications, nuclear staining in more than 5% of tumor cells is typically considered positive .

How do I select the appropriate NR4A3 antibody clone for my research?

Selection should be based on several factors:

• Target epitope: Different antibodies target distinct regions of NR4A3:

  • N-terminal region antibodies (AA 1-280)

  • DNA-binding domain antibodies (AA 292-364)

  • Ligand-binding domain antibodies (AA 414-521)

  • C-terminal region antibodies

• Species reactivity: Verify cross-reactivity with your model organism:

  • Human-specific antibodies

  • Multi-species reactive antibodies (human, mouse, rat)

  • Extended species reactivity (rabbit, cow, pig, dog)

• Clonality:

  • Polyclonal: Broader epitope recognition, potentially higher sensitivity

  • Monoclonal: Higher specificity, more consistent lot-to-lot

• Validated applications: Ensure the antibody has been validated for your specific application

For diagnostic applications in AciCC, studies have compared Santa Cruz Biotechnology and Origene antibody clones with 95% concordance, suggesting either can be reliable for clinical use .

What is the optimal protocol for NR4A3 immunohistochemistry in diagnostic applications?

Based on clinical validation studies, the following protocol has demonstrated high sensitivity and specificity for NR4A3 detection in AciCC diagnosis:

• Pretreatment: Heat-mediated antigen retrieval with Tris-EDTA buffer (pH 9, epitope retrieval solution 2) for 20 minutes

• Primary antibody: NR4A3 antibodies (1:100 dilution) - options include:

  • NOR-1 antibody, clone H-7 (Santa Cruz Biotechnology)

  • NR4A3 mouse monoclonal antibody, clone OTI2B11 (Origene Technologies)

• Incubation: 15 minutes at room temperature

• Detection system: Horseradish peroxidase-conjugated compact polymer system

• Chromogen: 3,3'-diaminobenzidine (DAB)

• Counterstaining: Hematoxylin

• Mounting: Leica Micromount or equivalent

• Interpretation: Consider positive when nuclear immunostaining is present in more than 5% of tumor cells with any intensity

This protocol has demonstrated excellent performance metrics for AciCC diagnosis:

• Sensitivity: 90-100%

• Specificity: 98.8-100%

• Positive predictive value: 92.3-100%

• Negative predictive value: 94.7-100%

How should I optimize western blotting protocols for NR4A3 detection?

For optimal western blot results with NR4A3 antibodies:

• Sample preparation:

  • Include protease inhibitors in lysis buffer

  • Nuclear extraction may improve signal due to NR4A3's nuclear localization

• Protein loading:

  • 20-50 μg of total protein per lane is typically sufficient

  • Expected molecular weight: 65-68 kDa

• Antibody selection and dilution:

  • Primary antibody: Start with 1:1000 dilution for most commercial NR4A3 antibodies

  • Secondary antibody: Species-appropriate HRP-conjugated, typically 1:5000-1:10000

• Controls:

  • Positive control: Skeletal muscle lysate (high NR4A3 expression)

  • Negative control: Tissues with minimal NR4A3 expression

  • Blocking peptide control to confirm specificity

• Interpretation:

  • Multiple bands may indicate different isoforms (alpha and beta)

  • Phosphorylation may alter migration pattern

  • Time-course experiments may show rapid induction followed by degradation

For detecting NR4A3 in response to stimuli (e.g., palmitic acid treatment), a time-course analysis is recommended as NR4A3 protein levels may show dynamic changes over 24 hours .

What is the tissue expression pattern of NR4A3 and how does this inform antibody validation?

NR4A3 shows distinctive tissue expression patterns that should be considered when validating antibodies:

High expression tissues (recommended positive controls):

• Skeletal muscle (highest expression, especially isoform alpha and beta)

• Salivary gland (particularly in acinic cell carcinoma)

• Pancreatic beta cells (relevant for insulin regulation studies)

Low or variable expression tissues:

• Fetal brain (low expression of isoform beta)

• Placenta (low expression of isoform beta)

• Most other normal tissues (minimal expression)

When validating a new NR4A3 antibody, skeletal muscle should serve as the primary positive control. For cancer studies, acinic cell carcinoma samples with confirmed NR4A3 expression provide excellent positive controls. Negative controls should include tissues known to lack NR4A3 expression or tissues from NR4A3 knockout models .

How does NR4A3 subcellular localization impact immunostaining interpretation?

NR4A3 primarily functions as a nuclear receptor and transcription factor, which has significant implications for immunostaining:

• Normal pattern: Strong nuclear staining with minimal cytoplasmic signal

  • In properly fixed and stained samples, >90% of NR4A3 immunoreactivity should be nuclear

• Abnormal patterns to be aware of:

  • Cytoplasmic granular staining may represent non-specific binding

  • Diffuse cytoplasmic staining without nuclear signal suggests technical issues

  • Mixed nuclear/cytoplasmic staining may occur in some contexts

• Technical considerations:

  • Nuclear antigen retrieval is critical (pH 9 Tris-EDTA buffer recommended)

  • Overfixation may mask nuclear epitopes

  • Interpretation criteria should specify nuclear staining (>5% of tumor cells)

In diagnostic applications for AciCC, only nuclear NR4A3 staining should be considered positive; cytoplasmic granular staining has been observed in non-AciCC neoplasms and represents non-specific binding .

How reliable is NR4A3 immunohistochemistry for diagnosing acinic cell carcinoma (AciCC) compared to other markers?

NR4A3 has emerged as a superior diagnostic marker for AciCC compared to previously used markers:

NR4A3 immunohistochemistry has been validated in multiple specimen types:

• Surgical resections (100% sensitivity)

• Cytology cell blocks (90% sensitivity)

• Direct smears (demonstrated utility)

NR4A3 staining is maintained in high-grade transformed AciCC cases, making it particularly valuable for difficult diagnostic scenarios. Performance is consistent across antibody clones from different vendors with 95% concordance .

What are the potential pitfalls in interpreting NR4A3 immunostaining results in diagnostic settings?

Several factors can complicate interpretation of NR4A3 immunostaining:

• False negatives:

  • Inadequate fixation or antigen retrieval

  • Improper antibody dilution

  • Insufficient incubation time

  • Sample age and storage conditions

• False positives:

  • Focal expression (5-10%) has been documented in high-grade mucoepidermoid carcinoma (1.2% of cases)

  • Non-specific cytoplasmic granular staining should not be interpreted as positive

  • Cross-reactivity with other NR4A family members (NR4A1, NR4A2)

• Interpretation challenges:

  • Using appropriate cutoff (>5% nuclear staining)

  • Distinguishing true nuclear from artifactual staining

  • Evaluating heterogeneous samples

• Technical recommendations:

  • Include appropriate positive and negative controls

  • Consider dual antibody clones in equivocal cases

  • Correlate results with morphology and other diagnostic markers

  • For cytology specimens, cell blocks show better performance than direct smears

How can NR4A3 antibodies be utilized to study the oncogenic functions of NR4A3 in cancer models?

NR4A3 has demonstrated oncogenic properties that can be investigated using antibodies in various experimental approaches:

• Chromatin immunoprecipitation (ChIP):

  • Use NR4A3 antibodies to identify direct transcriptional targets

  • Has revealed regulation of genes like Ccnd1 (cyclin D1) and Eno3

  • Protocol considerations: crosslinking optimization, sonication parameters, antibody concentration

• Proximity ligation assays:

  • Detect protein-protein interactions between NR4A3 and cofactors

  • Requires co-incubation with antibodies against potential interaction partners

• Immunoprecipitation followed by mass spectrometry:

  • Identify novel NR4A3 interacting proteins

  • Validate findings using reciprocal co-immunoprecipitation with NR4A3 antibodies

• Correlation studies:

  • Combine NR4A3 immunostaining with markers of proliferation, apoptosis, or other pathway components

  • Can help establish mechanistic relationships in tissue samples

• In experimental models:

  • Monitor NR4A3 expression in xenograft models using IHC/IF

  • Track changes in NR4A3 location and expression after drug treatments

  • Validate NR4A3 overexpression or knockdown in cell line models

Research has shown that NR4A3 overexpression promotes cell proliferation and increases the fraction of cells in S-phase, suggesting a direct role in cell cycle regulation. These findings have been validated in both mouse salivary gland and human mammary gland cell lines .

What is known about cross-reactivity between NR4A3 antibodies and other NR4A family members?

The NR4A family consists of three highly homologous nuclear receptors (NR4A1, NR4A2, and NR4A3), making specificity a critical consideration:

• Sequence homology regions:

  • Highest homology in the DNA-binding domain (~91-95%)

  • Moderate homology in the ligand-binding domain (~60-65%)

  • Lowest homology in the N-terminal activation domain (~20-30%)

• Recommended strategies to ensure specificity:

  • Select antibodies targeting unique regions, particularly the N-terminal domain

  • Validate using knockout/knockdown models of each family member

  • Perform peptide competition assays with specific blocking peptides

  • Consider side-by-side comparison of different antibody clones

• Functional redundancy implications:

  • Studies show considerable redundancy among NR4A family members in vivo

  • All three members can transactivate similar targets (e.g., Foxp3)

  • Distinguishing specific functions requires careful antibody selection and validation

When studying specific functions of NR4A3, researchers should consider the potential for compensation by other family members and validate findings using multiple approaches, including genetic models alongside antibody-based detection .

How can NR4A3 antibodies be employed to investigate the role of NR4A3 in insulin regulation and metabolic disease?

NR4A3 has been implicated in insulin regulation, providing opportunities for metabolic research:

• Experimental models:

  • Pancreatic beta cell lines (e.g., MIN6)

  • Palmitic acid-induced stress models

  • Stable cell lines expressing wild-type or mutant NR4A3

• Methodological approaches:

  • Immunostaining: Detect changes in NR4A3 expression and localization under metabolic stress conditions

  • ChIP-seq: Identify NR4A3 binding sites near insulin regulatory genes

  • Western blotting: Monitor dynamic changes in NR4A3 protein levels in response to fatty acids or other metabolic stressors

  • Co-immunoprecipitation: Identify interactions with other transcription factors involved in insulin gene regulation

• Domain-specific investigations:

  • Antibodies recognizing specific domains can help investigate the roles of:

    • Activation Function-1 (AF1) domain (AA 2-288)

    • DNA Binding Domain (DBD) (AA 292-364)

    • Ligand Binding Domain (LBD) (AA 398-626)

• Time-course considerations:

  • NR4A3 shows rapid upregulation in response to palmitic acid stress

  • Expression patterns correlate with ER stress markers like Chop and spliced XBP1

  • Time-course experiments should include early (2-4 hour) and late (12-24 hour) timepoints

Research has shown that NR4A3 may modulate insulin gene transcription indirectly, with complex and sometimes contradictory effects reported in different experimental systems .

What are the most common technical issues with NR4A3 antibodies and how can they be resolved?

Researchers frequently encounter several challenges when working with NR4A3 antibodies:

• Low signal intensity:

  • Potential causes: Insufficient antigen retrieval, low antibody concentration, low target expression

  • Solutions:

    • Optimize antigen retrieval (Tris-EDTA buffer, pH 9.0, 20 minutes)

    • Increase antibody concentration

    • Extend primary antibody incubation time

    • Use signal amplification systems

• High background:

  • Potential causes: Excessive antibody concentration, inadequate blocking, non-specific binding

  • Solutions:

    • Titrate antibody to optimal concentration

    • Increase blocking time/concentration

    • Add 0.1-0.3% Triton X-100 for better penetration

    • Include additional washing steps

• Cross-reactivity:

  • Potential causes: Antibody recognizing related NR4A family members

  • Solutions:

    • Select antibodies raised against unique regions of NR4A3

    • Validate with positive and negative controls

    • Consider peptide competition assays

    • Validate with genetic knockdown/knockout models

• Inconsistent results between experiments:

  • Potential causes: Lot-to-lot variation, inconsistent fixation, dynamic expression patterns

  • Solutions:

    • Standardize fixation protocols

    • Include consistent positive controls

    • Consider using monoclonal antibodies for greater consistency

    • Document lot numbers and maintain reference samples

• Nuclear versus cytoplasmic staining:

  • Potential causes: Fixation artifacts, true biological localization changes

  • Solutions:

    • Optimize fixation time

    • Ensure proper nuclear permeabilization

    • Compare with other nuclear markers

How do different sample preparation methods affect NR4A3 antibody performance?

Sample preparation significantly impacts NR4A3 antibody performance across different applications:

• Fixation effects:

  • Formalin fixation: Generally preserves NR4A3 epitopes but may require optimized antigen retrieval

  • Alcohol fixation: Works well for cytology specimens and can preserve some epitopes better than formalin

  • Fresh frozen: May provide better epitope preservation but poorer morphology

  • Recommendation: 10% neutral buffered formalin for 6-24 hours provides optimal results for most applications

• Antigen retrieval methods comparison:

  Method	Effectiveness	Recommended For	Less Suitable For
  Tris-EDTA pH 9.0 (heat)	Excellent	Most IHC/IF applications	-
  Citrate pH 6.0 (heat)	Moderate	Alternative if pH 9.0 unavailable	Primary choice
  Enzymatic retrieval	Poor	Not recommended	Most NR4A3 epitopes
  No retrieval	Very poor	Not recommended	All applications

• Sample type considerations:

  • Cell blocks: Reliable for NR4A3 detection (90-100% sensitivity)

  • Tissue sections: Excellent for NR4A3 IHC (100% sensitivity and specificity)

  • Direct smears: Can work but may require protocol adaptation

  • Frozen sections: Work well but may show higher background

• Storage impacts:

  • Fresh tissues: Optimal NR4A3 detection

  • Stored FFPE blocks: Epitope degradation possible after 5-10 years

  • Stored slides: Significant antigen loss after 3-6 months

  • Recommendation: Prepare fresh sections from blocks for optimal results

For cytology specimens specifically, both Santa Cruz and Origene NR4A3 antibody clones perform well, with 95% concordance in detection rates. NR4A3 immunostaining has been successfully demonstrated on direct smears from acinic cell carcinoma cases .

How might emerging technologies enhance the utility of NR4A3 antibodies in research and diagnostics?

Several emerging technologies hold promise for expanding NR4A3 antibody applications:

• Multiplexed immunofluorescence:

  • Simultaneous detection of NR4A3 with other markers

  • Applications in tumor microenvironment studies

  • Correlation with immune infiltrates or other nuclear receptors

• Mass cytometry (CyTOF):

  • Metal-tagged NR4A3 antibodies for high-dimensional single-cell analysis

  • Integration with surface markers and signaling molecules

  • Potential for biomarker discovery in complex tissues

• Spatial transcriptomics integration:

  • Combining NR4A3 protein detection with spatial mRNA analysis

  • Correlation of protein expression with transcriptional signatures

  • Enhanced understanding of heterogeneity within tissues

• Live-cell imaging technologies:

  • Nanobodies or Fab fragments against NR4A3 for real-time dynamics

  • CRISPR knock-in fluorescent tags for endogenous monitoring

  • Study of NR4A3 trafficking between nucleus and cytoplasm

• Digital pathology and AI analysis:

  • Automated quantification of NR4A3 immunostaining

  • Pattern recognition for diagnostic applications

  • Integration with other biomarkers for enhanced diagnostic accuracy

These technologies could significantly expand our understanding of NR4A3 biology beyond current applications in cancer diagnosis and basic research .

What are the most promising research questions regarding NR4A3 function that could be addressed using antibody-based approaches?

Several key research questions about NR4A3 function remain to be fully explored:

• Transcriptional regulation mechanisms:

  • How does NR4A3 selectively regulate target genes?

  • What co-factors interact with NR4A3 to modulate specificity?

  • How do post-translational modifications affect NR4A3 activity?

  Approaches: ChIP-seq with NR4A3 antibodies, Co-IP followed by mass spectrometry, Antibodies against modified forms of NR4A3

• Tumor biology:

  • How does enhancer hijacking lead to NR4A3 overexpression in AciCC?

  • What downstream pathways mediate NR4A3's oncogenic effects?

  • Can NR4A3 serve as a therapeutic target?

  Approaches: IHC in patient cohorts, Correlation with clinical outcomes, Functional studies in cell lines and animal models

• Metabolic regulation:

  • How does NR4A3 regulate insulin production in response to stress?

  • What is the role of NR4A3 in lipid metabolism and obesity?

  • How do the three NR4A family members functionally compensate for each other?

  Approaches: Time-course studies with metabolic stressors, Combined knockdown approaches, Domain-specific antibodies

• Tissue-specific functions:

  • Why is NR4A3 highly expressed in skeletal muscle?

  • What determines the tissue-specific activities of NR4A3?

  • How do different isoforms contribute to tissue-specific functions?

  Approaches: Isoform-specific antibodies, Tissue microarrays, Conditional knockout models

• Therapeutic implications:

  • Can NR4A3 inhibition serve as a therapeutic strategy in AciCC?

  • How does NR4A3 expression correlate with treatment response?

  • Can NR4A3 be targeted in metabolic diseases?

  Approaches: Pharmacological modulation followed by antibody detection, Patient-derived xenograft models, Clinical correlation studies